CAMBRIDGE, Mass.--(BUSINESS WIRE)--Unum Therapeutics, a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, today announced that the Company has been selected for two poster presentations on its Antibody-Coupled T-Cell Receptor (ACTR) platform at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy 2016 Meeting. The conference will take place on October 20-23, 2016 at the Boston Marriott Copley Place in Boston, MA.
Presentation Details:
Presentation Title: Efficient targeting of HER‐2‐positive cancers
by Antibody‐Coupled T cell Receptor (ACTR) engineered autologous T cells
Presenter:
Casey B. Judge
Presentation Date: Friday, October 21,
2016
Presentation Time: 5:15 p.m.‐7:45 p.m.
Room:
Back Bay Room
Abstract Number: A77
Presentation Title: High throughput triage of the ACTR platform
demonstrates broad activity across multiple tumor targets
Presenter:
Eugene Choi
Presentation Date: Saturday, October 22, 2016
Presentation
Time: 6:00 p.m.‐8:45 p.m.
Room: Back Bay Room
Abstract
Number: B60
The posters will be posted on Unum’s website following the presentations.
About Antibody-Coupled T-cell Receptor (ACTR) Technology and ACTR087
Unum’s proprietary ACTR is a chimeric protein that combines components from receptors normally found on two different human immune cell types – natural killer (NK) cells and T-cells – to create a novel cancer cell killing activity. T-cells bearing the ACTR receptor protein can be directed to attack a tumor by combining with a monoclonal antibody that binds antigens on the cancer cell surface.
In contrast to other T-cell therapy approaches for cancer that are limited to a single cancer cell surface target and, therefore, treat a narrow set of tumors, Unum’s approach is not restricted by a specific tumor cell antigen and, thus, may have applications for treating many different types of cancers when combined with the right antibody.
Unum is developing ACTR in combination with a range of tumor-targeting antibodies for use in both hematologic and solid tumor indications. ACTR087, Unum’s most advanced product candidate, combines Unum’s proprietary ACTR, with rituximab, an anti-CD20 antibody. The ACTR087 study will be the first clinical trial using a viral vector to permanently insert the ACTR gene into the genome of patient T-cells.
About Unum Therapeutics
Unum Therapeutics uses its proprietary Antibody-Coupled T-cell Receptor (ACTR) technology in combination with tumor-targeting antibodies, which is designed to activate the body’s own immune system to fight cancer. Unum is actively building a pipeline of ACTR programs in which proprietary, tumor-targeting antibodies are armed to improve their therapeutic potential. The Company is headquartered in Cambridge, MA. For more information, visit www.unumrx.com/.
